Develop and Validate Ultrasonic Device for Osteoporotic Fracture Risk Assessment
NCT ID: NCT01123421
Last Updated: 2012-10-15
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
113 participants
OBSERVATIONAL
2010-05-31
2012-02-29
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Keywords
Explore important study keywords that can help with search, categorization, and topic discovery.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
CASE_CONTROL
RETROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
With osteoporotic fracture
Approximately 100 postmenopausal women that have been enrolled in a population-based case-control study that have experienced a clinically-diagnosed fracture of thoracolumbar spine or distal forearm due to minimal or moderate trauma based on review on their inpatient and outpatient medical records will be enrolled.
No interventions assigned to this group
Without osteoporotic fracture
Approximately 100 control women will have no history of a prior spine, hip, or wrist fracture.
No interventions assigned to this group
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* postmenopausal women no history of fracture at spine or wrist
Exclusion Criteria
* stroke
* tibia fracture or surgery
* BMI ≥ 35 kg/m2
* Teriparatide use currently or within the past 6 months,
* Any skin issues (open wounds or rashes, and/or skin infections) of the tibial area.
FEMALE
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
National Institutes of Health (NIH)
NIH
National Institute on Aging (NIA)
NIH
Mayo Clinic
OTHER
Artann Laboratories
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Armen Sarvazyan, Ph.D., D.Sc.
Role: PRINCIPAL_INVESTIGATOR
Artann Laboratories, Inc.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Mayo Clinic Rochester
Rochester, Minnesota, United States
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
BUSS03
Identifier Type: -
Identifier Source: org_study_id